Join Tara Crawford-Parks, PhD, Director for Translational R&D and Product Enablement at DNA Genotek, to explore the potential of first void urine biomarkers in clinical diagnostics. Discover how this non-invasive sampling method is transforming HPV screening and opening new possibilities for early disease detection in oncology and infectious diseases. Learn about the science behind first void urine collection, its advantages over traditional sampling methods, and how innovative devices like the Colli-Pee™ are supporting more accessible healthcare for underserved populations worldwide.